Dr Reddys Laboratories Ltd 6-K, filed Mar 17, 2022
Dr Reddys Laboratories Ltd (RDY)
About this 6-K
Dr Reddys Laboratories Ltd filed this 6-K on March 17, 2022.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
March, 2022
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
|
Exhibit |
Description of Exhibits | |
| 99.1 | Intimation dated March 17, 2022 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED (Registrant) | |||||||
| Date: March 17, 2022 | By: | /s/ Parag Agarwal | |||||
| Name: | Parag Agarwal | ||||||
| Title: | Chief Financial Officer | ||||||
Exhibit 99.1
 |
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507
Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com |
March 17, 2022
To,
The Secretary
BSE Limited
National Stock Exchange of India Ltd.
New York Stock Exchange Inc.
NSE IFSC Limited
Dear Sir/Madam,
Sub: Appointment of Company Secretary and Compliance Officer
Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
With reference to the above mentioned subject, we are pleased to inform that based on the recommendation of Nomination, Governance and Compensation Committee, the Board of Directors of the Company at their meeting held on March 17, 2022, approved the appointment of Mr. K Randhir Singh (ICSI Membership Number- F6621) w.e.f. March 17, 2022, as the Company Secretary and Compliance Officer (being the Key Managerial Personnel) of the Company, pursuant to the provisions of Section 203 of the Companies Act, 2013 and Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Consequent to the said appointment, Mr. Vivek Mittal, Global General Counsel of the Company, who had been appointed as an Interim Compliance Officer w.e.f. November 19, 2021, ceases to act as such with immediate effect.
The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, with respect to the above appointment of Company Secretary and Compliance Officer are enclosed as Annexure A.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
| /s/ G V Prasad | ||
| G V Prasad | ||
| Co-Chairman & Managing Director | ||
| DIN: 00057433 |
Annexure A
Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015
Details of Mr. K Randhir Singh
| S. No. | Particulars | Remarks |
| 1 | Reason for change | Appointment |
| 2 |
Date of appointment
Term of appointment |
March 17, 2022
As per the policy of the Company.
|
| 3 | Brief profile |
Mr. K Randhir Singh is a Fellow member of the Institute of Company Secretaries of India. He has done LLB & B. Com (Hons) from Delhi University. He has Post Graduate Diploma in Management with specialization in finance from Lal Bahadur Shastri Institute of Management (LBSIM), New Delhi.
Mr. Singh has over 19 years of extensive experience in corporate governance, compliance, corporate laws, board process and legal. Prior to joining Dr. Reddy’s Laboratories Limited, Mr. Singh worked as Company Secretary and Compliance Officer of Colgate Palmolive India Limited. Prior to joining Colgate, Mr. Singh held managerial positions with reputed organizations, like GE Capital, NIIT, Bhartiya.
|
| 4 | Disclosure of relationships between directors | Not Applicable |
Details of Mr. Vivek Mittal
| S. No. | Particulars | Remarks |
| 1 | Reason for change | Cessation as interim compliance officer |
| 2 |
Date of cessation
Term of appointment |
March 17, 2022
Not applicable
|
| 3 | Brief profile | Not applicable |
| 4 | Disclosure of relationships between directors | Not applicable |
